BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9890806)

  • 21. Molecular screening of FRAXA and FRAXE in Indian patients with unexplained mental retardation.
    Pandey UB; Phadke S; Mittal B
    Genet Test; 2002; 6(4):335-9. PubMed ID: 12537661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 10 years' experience in fragile X testing among mentally retarded individuals in Greece: a molecular and epidemiological approach.
    Sofocleous C; Kitsiou S; Fryssira H; Kolialexi A; Kalaitzidaki M; Roma E; Tsangaris GT; Chistofidou C; Metaxotou C; Kanavakis E; Mavrou A
    In Vivo; 2008; 22(4):451-5. PubMed ID: 18712171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fragile X syndrome is less common than previously estimated.
    Morton JE; Bundey S; Webb TP; MacDonald F; Rindl PM; Bullock S
    J Med Genet; 1997 Jan; 34(1):1-5. PubMed ID: 9032640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of the fragile-X syndrome in mentally retarded boys in a Swedish county.
    Gustavson KH; Blomquist HK; Holmgren G
    Am J Med Genet; 1986; 23(1-2):581-7. PubMed ID: 3953668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular screening for fragile X syndrome in mentally handicapped children in Korea.
    Kwon SH; Lee KS; Hyun MC; Song KE; Kim JK
    J Korean Med Sci; 2001 Jun; 16(3):271-5. PubMed ID: 11410685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for fragile X syndrome.
    Murray J; Cuckle H; Taylor G; Hewison J
    Health Technol Assess; 1997; 1(4):i-iv, 1-71. PubMed ID: 9414543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragile X screening program in New York State.
    Nolin SL; Snider DA; Jenkins EC; Brown WT; Krawczun M; Stetka D; Houck G; Dobkin CS; Strong G; Smith-Dobransky G
    Am J Med Genet; 1991; 38(2-3):251-5. PubMed ID: 2018068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnosis and genetic counseling for fragile X mental retardation.
    Pandey UB; Phadke SR; Mittal B
    Neurol India; 2004 Mar; 52(1):36-42. PubMed ID: 15069237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical, cytogenetic and molecular aspects of fragile X syndrome].
    Veenema H
    Tijdschr Kindergeneeskd; 1989 Oct; 57(5):153-8. PubMed ID: 2683200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA analysis of the fragile X syndrome in an at risk pediatric population in croatia: simple clinical preselection criteria can considerably improve the cost-effectiveness of fragile X screening studies.
    Hećimović S; Barisić I; Pavelić K
    Hum Hered; 1998; 48(5):256-65. PubMed ID: 9748695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of fragile X pre-mutation carriers in the Chinese obstetric population using a robust FMR1 polymerase chain reaction assay: implications for screening and prenatal diagnosis.
    Cheng YK; Lin CS; Kwok YK; Chan YM; Lau TK; Leung TY; Choy KW
    Hong Kong Med J; 2017 Apr; 23(2):110-6. PubMed ID: 28253484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Children with the fragile X chromosome at schools for the mildly mentally retarded.
    Thake A; Todd J; Webb T; Bundey S
    Dev Med Child Neurol; 1987 Dec; 29(6):711-9. PubMed ID: 3691971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of fragile X(A) syndrome in mentally retarded children at a genetics referral centre in Delhi, India.
    Jain U; Verma IC; Kapoor AK
    Indian J Med Res; 1998 Jul; 108():12-6. PubMed ID: 9745213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular screening for fragile X syndrome in Thailand.
    Limprasert P; Ruangdaraganon N; Sura T; Vasiknanonte P; Jinorose U
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 2():114-8. PubMed ID: 11400746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical screening score for the fragile X (Martin-Bell) syndrome.
    Laing S; Partington M; Robinson H; Turner G
    Am J Med Genet; 1991; 38(2-3):256-9. PubMed ID: 2018069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic cytogenetic study of a population of 1170 mentally retarded and/or behaviourly disturbed patients including fragile X-screening. The Hondsberg experience.
    Schreppers-Tijdink GA; Curfs LM; Wiegers A; Kleczkowska A; Fryns JP
    J Genet Hum; 1988 Dec; 36(5):425-46. PubMed ID: 2975324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genetics of Fragile X syndrome and its prevention].
    Boué J; Simon-Bouy B
    J Gynecol Obstet Biol Reprod (Paris); 1997; 26(3):273-9. PubMed ID: 9265049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Martin-Bell syndrome in South Africa.
    Venter PA; Op't Hof J; Coetzee DJ
    Am J Med Genet; 1986; 23(1-2):597-610. PubMed ID: 3953670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [From gene to disease; fragile X-syndrome: hereditary mental retardation due to a developmental gene].
    de Vries LB; Oostra BA
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):474-6. PubMed ID: 11268909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic checklist to screen for fragile X syndrome in people with mental retardation.
    Maes B; Fryns JP; Ghesquière P; Borghgraef M
    Ment Retard; 2000 Jun; 38(3):207-15. PubMed ID: 10900928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.